Previous Close | 9.08 |
Open | 8.96 |
Bid | 9.02 x 100 |
Ask | 9.10 x 100 |
Day's Range | 8.68 - 9.11 |
52 Week Range | 2.74 - 12.00 |
Volume | |
Avg. Volume | 2,018,445 |
Market Cap | 2.004B |
Beta (5Y Monthly) | 1.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Director Patrick Yang has sold 25,000 shares of Sana Biotechnology Inc (NASDAQ:SANA), according to a recent SEC Filing.
Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently expanded its investment portfolio by adding a significant number of shares in Sana Biotechnology Inc (NASDAQ:SANA). This move underscores the firm's confidence in the biotechnology company's growth potential. On February 1, 2024, Baillie Gifford (Trades, Portfolio) acquired an additional 210,603 shares of Sana Biotechnology, reflecting a 2.07% change in their holdings and bringing the total shares owned to 10,360,620.
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]